Loading organizations...
Loading organizations...
Develops small molecule inhibitors for advanced cancer treatment.
Incyclix Bio has raised $47.3M across 3 funding rounds.
Incyclix Bio has raised $47.3M in total across 3 funding rounds.
Incyclix Bio has raised $47.3M in total across 3 funding rounds.
Incyclix Bio's investors include Cape Fear BioCapital, Eli Lilly and Company, Fred Eshelman, Pharmacosmos, Sid Subramony, Nathaniel Brooks Horwitz.
Incyclix Bio has raised $47.3M across 3 funding rounds. Most recently, it raised $11.3M Series B Extension in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 25, 2025 | $11.3M Series B Extension | Cape Fear BioCapital, Eli Lilly and Company, Fred Eshelman, Pharmacosmos | |
| Apr 4, 2022 | $30.0M Series B | Sid Subramony | Fred Eshelman, Nathaniel Brooks Horwitz |
| Aug 5, 2020 | $6.0M Other Equity | Fred Eshelman |